Getting personal with neoantigen-based therapeutic cancer vaccines.
Cancer Immunol Res
Authors | |
Keywords | |
Abstract | Despite years of preclinical efforts and hundreds of clinical studies, therapeutic cancer vaccines with the routine ability to limit or eliminate tumor growth in humans have been elusive. With advances in genome sequencing, it is now possible to identify a new class of tumor-specific antigens derived from mutated proteins that are present only in the tumor. These "neoantigens" should provide highly specific targets for antitumor immunity. Although many challenges remain in producing and testing neoantigen-based vaccines customized for each patient, a neoantigen vaccine offers a promising new approach to induce highly focused antitumor T cells aimed at eradicating cancer cells. |
Year of Publication | 2013
|
Journal | Cancer Immunol Res
|
Volume | 1
|
Issue | 1
|
Pages | 11-5
|
Date Published | 2013 Jul
|
ISSN | 2326-6074
|
DOI | 10.1158/2326-6066.CIR-13-0022
|
PubMed ID | 24777245
|
PubMed Central ID | PMC4033902
|
Links | |
Grant list | 1R01CA155010-02 / CA / NCI NIH HHS / United States
5 R01 HL103532-03 / HL / NHLBI NIH HHS / United States
R01 CA155010 / CA / NCI NIH HHS / United States
|